Information Provided By: 
Fly News Breaks for June 17, 2015
AAVL, BLUE
Jun 17, 2015 | 08:52 EDT
Maxim attributes the weakness yesterday in shares of bluebird bio (BLUE) to disappointment around Avalanche Biotechnologies' (AAVL) anti-VEGF gene therapy study for wet age-related macular degeneration. The firm says it's too early to tell if Avalanche failed and that its thesis on bluebid remains unchanged. It recommends buying bluebird on weakness and keeps a Buy rating on the name with a $190 price target.
News For BLUE;AAVL From the Last 2 Days
There are no results for your query BLUE;AAVL
